DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Selpercatinib
Selpercatinib
Cogent Biosciences Announces Creation of Cogent Research Team
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib a C Ezra Y
Selpercatinib LOXO-292 LY3527723
Prescribing Information
RET Inhibition in Novel Patient-Derived Models of RET Fusion
Oncology Oral, Lung Cancer Therapeutic Class Review (TCR)
And Off-Target Resistance Mutations in an EML4-ALK Positive Non-Small Cell Lung Cancer Patient Under ALK Inhibition
Progresses Toward Precision Medicine in RET-Altered Solid Tumors Carmen Belli1, Santosh Anand2,3, Justin F
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Strengthening the Accelerated Approval Pathway: an Analysis of Potential Policy Reforms and Their Impact on Uncertainty, Access, Innovation, and Costs
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion- Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Targeted Therapy for Lung Cancer (Faculty Presentations)
Westfield USHP Slides Handout
January 2021 L.A. Care Health Plan Medi-Cal Formulary
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer
Oncology Approvals in 2020: a Year of Firsts in the Midst of a Pandemic
Top View
Bladder Cancer
Potential Exploration of Recent FDA-Approved Anticancer Drugs Against Models of SARS-Cov-2’S Main Protease and Spike Glycoprotein: a Computational Study
Application Number
Selpercatinib (Retsevmo®) for the Treatment of RET-Fusion Positive
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Clinical Criteria, Step Therapy, and Quantity Limits for Tenncare Preferred Drug List (PDL) September 1, 2021
E-Learning New Systemic Treatment Options for Radioiodine-Refractory Differentiated and Medullary Thyroid Cancers
Oncology Center of Excellence 2020 Annual Report
Informing Treatment Strategies Through a Comprehensive Approach
TAG Mail – 25 June 2020
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Oncology Agents Policy #: Rx.01.67
Tumour-Agnostic Therapies
Optimizing Use of Biomarkers in Managing Metastatic Non−Small Cell Lung Cancer the Role of the Oncology Health Care Team Faculty Information
Precision Medicine in Oncology: a Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Current Targeted Therapies for the Fight Against Non-Small Cell Lung Cancer
CY 2020 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2020
20200826 Patel Lung Cancer HANDOUT
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
List Item Applications for New Human
Avapritinib 03/20
Tyrosine Kinase Inhibitors - Oral
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Pralsetinib (Gavreto™) EOCCO POLICY
Retsevmo, INN-Selpercatinib
Clinical Trials Appendix Q1 2021 Results Update
Analysis of Resistance Mechanisms to Pralsetinib (Blu-667) in Patients with Ret Fusion–Positive Non-Small Cell Lung Cancer (Nsclc) from the Arrow Study
New Drug Is a Triple Threat Against RET-Altered Cancer
Download Overview
Molecular Analysis for Targeted Therapy Or Immunotherapy of Non-Small-Cell Lung Cancer
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
Comprehensive Genomic Profiling Comprehensive FAST FACTS Genomic Profiling Comprehensive Genomic Profiling
2020 Annual Report
Prior Authorization Criteria
Tyrosine Kinase Receptors in Oncology